Targeting moiety-drug grafted immune cell compositions and methods of use
AssigneesArizona Board of Regents on Behalf of the University of Arizona, University of Utah Research Foundation
InventorsYoungwook Won, David A. Bull, Daniel Yongwon Lee
Life of this patent
Estimating the term…
Abstract
Surface-engineered immune cells, such as natural killer cells, grafted with targeting moiety-drug complexes. The present invention combines chemotherapy and immunotherapy by engineering the immune cells to target specific tumor cells through antigen recognition and deliver potent chemotherapeutic agents, thereby destroying the tumor cells. The surface-engineered immune cells may be prepared using a one-step method. The present invention also provides kits for preparing the surface-engineered immune cells.
Claims8
A chemoimmunotherapeutic composition for targeting a HER2 expressing cancer cell, said composition comprising:
- a) a targeting moiety specific for and capable of binding to a target on a cell of interest, wherein the targeting moiety is trastuzumab;
- b) a drug conjugated to the targeting moiety forming a targeting moiety-drug complex, wherein the drug is emtansine (DM1);
- c) a phospholipid linked to a polyethylene glycol (PEG) forming a phospholipid-PEG linker, wherein the phospholipid-PEG linker is attached to the targeting moiety-drug complex;
- and
- d) an immune cell, wherein the targeting moiety-drug complex is hydrophobically bound to the immune cell via the phospholipid-PEG linker, wherein the immune cell is a natural killer (NK) cell;
- wherein the targeting moiety-drug complex directs the immune cell to the cell of interest,
- wherein the drug has a cytotoxic effect on the cell of interest.
A method of treating a HER2 expressing tumor in a subject in need thereof, comprising administering a chemoimmunotherapeutic composition comprising:
- a) a targeting moiety specific for and capable of binding to a target on a cell of interest wherein the targeting moiety is trastuzumab;
- b) a drug conjugated to the targeting moiety forming a targeting moiety-drug complex, wherein the drug is emtansine (DM1);
- c) a phospholipid linked to a polyethylene glycol (PEG) forming a phospholipid-PEG linker, wherein the phospholipid-PEG linker is attached to the targeting moiety-drug complex;
- and
- d) an immune cell, wherein the targeting moiety-drug complex is hydrophobically bound to the immune cell via the phospholipid-PEG linker, wherein the immune cell is a natural killer (NK) cell;
- wherein the targeting moiety-drug complex directs the immune cell to the cell of interest,
- wherein the drug has a cytotoxic effect on the cell of interest.
Dependencies are inferred from the claim text.